ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
83,265
0,60%
Bitcoin
63 837,17
-0,09%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Galmed Pharmaceuticals Ltd (GLMD)

  7. Galmed Pharmaceuticals Ltd (GLMD) Actualités

GLMD

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GLMD
DateHeureSourceTitreSymboleSociété
04/04/202423h06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
15/03/202414h00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/02/202420h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
30/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/11/202322h48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202322h37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202322h32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202314h30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202322h05PR Newswire (US)Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202313h30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/07/202316h12Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202315h23Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202315h30PR Newswire (US)Galmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingNASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/07/202323h08Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202314h00PR Newswire (US)Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202314h41Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202314h40Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202314h38Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
16/06/202322h17Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/06/202314h14Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/06/202314h00PR Newswire (US)Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/05/202313h00PR Newswire (US)Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/03/202323h00PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/03/202322h32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
08/02/202314h00PR Newswire (US)Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltNASDAQ:GLMDGalmed Pharmaceuticals Ltd
04/01/202314h00PR Newswire (US)Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/12/202223h00PR Newswire (US)Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
17/11/202212h25TipRanksH.C. Wainwright Remains a Hold on Galmed Pharmaceuticals (GLMD)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
08/08/202212h25TipRanksH.C. Wainwright Keeps Their Hold Rating on Galmed Pharmaceuticals (GLMD)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
04/08/202214h00PR Newswire (US)Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:GLMD

Dernières Valeurs Consultées

EU
ACA
Credit Agricole
EU
GLE
Societe Generale
EU
AF
Air FranceKLM
NASDAQ
NVDA
NVIDIA
NASDAQ
MSFT
Microsoft
EU
VIV
Vivendi
NYSE
MRK
Merck
EU
RI
Pernod Ricard
EU
CS
Axa
NYSE
NKE
Nike
EU
MC
Lvmh Moet Hennessy Louis...
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés